| Literature DB >> 1448425 |
N Bodor1, T Loftsson, W M Wu.
Abstract
The soft corticosteroid, loteprednol etabonate (chloromethyl 17 alpha-ethoxycarbonyloxy-11 beta-hydroxy-3-oxoandrosta-1,4-diene-17 beta-carboxylate), I, was designed based on the "inactive metabolite approach." Accordingly, I should be metabolized by hydrolysis to the corresponding inactive cortienic acid derivative, II. The in vitro and in vivo metabolism of I indeed yielded mainly this inactive metabolite, which is more hydrophilic and thus readily eliminated from the body. Relatively high levels of I were found in tissues after intravenous administration of the drug in rats. The permeability of I through hairless mouse skin was comparable to what has been found for related "hard" steroids, without significant metabolism taking place in the skin.Entities:
Mesh:
Substances:
Year: 1992 PMID: 1448425 DOI: 10.1023/a:1015849132396
Source DB: PubMed Journal: Pharm Res ISSN: 0724-8741 Impact factor: 4.200